LOGIN OR REGISTER
Course Library

Addressing Type 2 Inflammation in Atopic Dermatitis: Individualizing Treatment

Dermatology
Curriculum:
Addressing Type 2 Inflammation in Atopic Dermatitis: Individualizing Care Across Populations
Credits:
.25 AMA PRA Category 1 Credit(s) ™ .25 AANP Contact Hours .25 Pharmacology
Launch Date:
July 01, 2019
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Dermatologists, Primary Care Physicians, Pediatricians, Nures Practitioners, Physician Assistants, Managed Care

Relevant Terms:

Atopic dermatitis, eczema

Brad P. Glick, DO, MPH, FAAD, FAOCD

Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs
Deputy Chair, Individual Giving Committee, AAD
Vice President, Florida Society for Dermatology and Dermatologic Surgery
Clinical Assistant Professor of Dermatology
Herbert Wertheim College of Medicine
Miami, Florida

Dr. Brad Glick is a board certified dermatologist and dermatologic surgeon with clinical and academic practices in South Florida. He is the Director of the Dermatology Residency at the Larkin Hospital, Palm Springs and Clinical Assistant Professor of Dermatology at the Herbert Wertheim College of Medicine Miami, Florida. Dr. Glick is also Director, and Principal Investigator for GSI Clinical Research in Margate, Florida as well as the current Vice President for the Florida Society for Dermatology and Dermatologic Surgery.

Dr. Glick’s Dermatology residency training was performed at the Greater Miami Skin and Laser Center at Mount Sinai Medical Center, Miami Beach, Florida where he earned certificates in Dermatologic, Mohs Micrographic, and Laser Surgery.

He is a Diplomate of the American Osteopathic Board of Dermatology, American Osteopathic Board of Family Practice, and National Board of Osteopathic Medical Examiners. Dr. Glick has also served as past President of the American Osteopathic College of Dermatology (AOCD), President of the Foundation for Osteopathic Dermatology (FOD), and past President of the Broward County Dermatologic Society. 

Linda Stein Gold, MD, FAAD

Director of Dermatology Clinical Research
Division Head of Dermatology
Henry Ford Health System
West Bloomfield, Michigan

Dr. Linda Stein Gold is Director of Dermatology Clinical Research for the Henry Ford Health System in Detroit, Michigan. She is also Division Head of Dermatology for the Henry Ford Health System in West Bloomfield, Michigan. Dr. Stein Gold is on the Board of Directors of the American Academy of Dermatology and a member of its Executive, Priorities, Corporate Relations, and Budget Committees. She has authored more than 75 articles published in journals including Journal of the American Academy of Dermatology, Journal of Dermatological Treatment, Pediatric Dermatology, Journal of Clinical and Aesthetic Dermatology, and Seminars in Cutaneous Medicine and Surgery.

Dr. Stein Gold is a frequent national and international lecturer on the areas of psoriasis, alopecia, viral infections, atopic dermatitis, and fungal infections. Her recent research has focused on treatments for papulopustular rosacea, acne vulgaris, plaque-type psoriasis, atopic dermatitis, and alopecia areata.

Dr. Stein Gold is a frequent national and international lecturer on the areas of psoriasis, alopecia, viral infections, atopic dermatitis, and fungal infections. Her recent research has focused on treatments for papulopustular rosacea, acne vulgaris, plaque-type psoriasis, atopic dermatitis, and alopecia areata.

Mercedes E. Gonzalez, MD

Medical Director, Pediatric Dermatology of Miami
Clinical Assistant Professor, Dr. Phillip Frost Department of Dermatology
University of Miami Miller School of Medicine
Clinical Assistant Professor
Herbert Wertheim College of Medicine, Florida International University
Miami, Florida

Dr. Mercedes E. Gonzalez is the Medical Director of Pediatric Dermatology of Miami, a private practice in Miami, FL and serves as a clinical assistant professor of dermatology at the Florida International University Herbert Wertheim College of Medicine, University of Miami Miller School of Medicine and at the Larkin Residency Program.

Dr. Gonzalez earned her medical degree from Rutgers –UMDNJ Medical School in Newark, NJ and trained in pediatrics at Columbia University and in dermatology at New York University.  She completed fellowships in pediatric dermatology at New York University and at the University of Miami.  She is Board certified in Pediatrics, Dermatology and Pediatric Dermatology. She is an active member of several committees of the American Academy of Dermatology, American Board of Dermatology and Society for Pediatric Dermatology.

Dr. Gonzalez has published over 30 journal articles, contributed to multiple dermatology textbooks, and spoken at numerous dermatology conferences. She is also the co-editor of the 4th edition of Goodheart’s Photoguide to Common Skin Disorders, a picture-based dermatology textbook.   In addition, she is a principal investigator in numerous pediatric clinical trials. 

1. Individualize AD treatment with consideration to the full spectrum of treatment options and disease severity
2. Recognize the risks and safety profiles of current treatments for effective AD management

PROGRAM OVERVIEW:

Atopic dermatitis (AD) is a multifactorial, chronic inflammatory and heterogeneous disorder that affects up to 20% of children and up to 3% of adults.  The disease is characterized by intense itching, secondary skin infections, and recurrent eczematous lesions, and poses a significant burden on healthcare resources and patients' quality of life.

There is a wide variation in knowledge, competence and practice patterns among clinicians regarding the assessment and management of atopic dermatitis and its comorbidities. 

DISCLOSURE POLICY STATEMENT:

It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.

While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.

Planning Committee

Sandy Bihlmeyer, M.Ed.

Senior Project Manager

National Association for Continuing Education


Plantation, FL

 

Michelle Frisch, MPH, CHCP

Vice-President

National Association for Continuing Education


Plantation, FL

 

Daniela Hiedra

Activity Director

National Association for Continuing Education

Plantation, FL

 

Wendy Gloffke, PhD

Medical Writing & Communications

Scranton, PA

 

Gregg Sherman, MD

Chief Medical Officer

National Association for Continuing Education

Plantation, FL

DISCLOSURE OF CONFLICTS OF INTEREST:

Faculty

Dr. Glick serves on the speaker’s bureau for SunPharma, Abbvie, Janssen, Celgene, Lilly, Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Sanofi Regeneron, Dermira, Pfizer, Dermavant, and Sanofi Genzyme. He is also an advisor for Dermavant, Pfizer, Sanofi Genzyme, Dermira, Novartis, Lilly, SunPharma, Celgene and Abbvie; and an investigator for Abbvie, Celgene, Dermavant and ChemoCentryx.

Dr. Gonzalez is a member of the Advisory Board at Pfizer, Regeneron and Verrica Pharmaceuticals. She is also a speaker and principal investigator for Pfizer, AbbVie, and Regeneron; and an independent contractor for Unilever and Verrica Pharmaceuticals.

Dr. Stein Gold is a consultant for Pfizer, Dermavant and Sanofi Regeneron; and an advisor for Leo Pharma, Dermira, Pfizer and Sanofi Genzyme. She is also a speaker for Leo Pharma, Pfizer, Sanofi Regeneron and Sanofi Genzyme; and a Principal Investigator for Abbott, Leo Pharma, Dermira, Abbvie, Incyte and Pfizer.

Planning Committee

Michelle Frisch has no real or apparent conflicts of interest to report. 

Gregg Sherman, MD, has no real or apparent conflicts of interest to report. 

Sandy Bihlmeyer, M.Ed., has no real or apparent conflicts of interest to report. 

Daniela Hiedra has no real or apparent conflicts of interest to report. 

Wendy Gloffke, PhD, has no real or apparent conflicts of interest to report.  

 

DISCLOSURE OF UNLABELED USE:

NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

 DISCLAIMER:

The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.

 ACCREDITATION STATEMENT:

The National Association for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners.  AANP Provider Number 121222. 

This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.

For CME questions, please contact NACE at info@naceonline.com

Contact this CME provider for privacy and confidentiality policy statement information at:

https://www.naceonline.com/privacy_policy.php

CREDIT DESIGNATION STATEMENT:

NACE designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners.  AANP Provider Number 121222.  This program has been approved for 0.25 contact hours of continuing education (which includes 0.25 hours of pharmacology).

TO OBTAIN CME CREDITS:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit.
  • Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
  • You must score 60% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE FORMAT/MEDIUM: Enduring Material

ESTIMATED TIME TO COMPLETE: 15 minutes

ACKNOWLEDGEMENT:

This activity is sponsored by National Association for Continuing Education.

This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

If you have any questions regarding this activity, send an email to info@naceonline.com.

Copyright © 2019 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.

COURSE VIEWING REQUIREMENTS:

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above



 
   

 

 

Schedule an event with a Standardized Patient
×